3.5.5. cardiovascular disease. evidence suggests hypogonadal men increased risk cvd . whether loh cause consequence atherosclerosis clearly determined. late-onset hypogonadism associated cv risk factors, including central obesity, insulin resistance hyperglycaemia, dyslipidaemia, pro-thrombotic tendency chronic inflammatory state . atherosclerosis chronic inflammatory disease, releases pro-inflammatory cytokines circulation, known suppress testosterone release hpg axis. evidence rcts testosterone therapy men mets and/or t2dm demonstrates benefit cv risk, including reduced central adiposity, insulin resistance, total cholesterol ldl-cholesterol suppression circulating cytokines [28-30,35,147,148]. however, due equivocal nature studies, testosterone therapy cannot recommended use outside treatment specific symptoms. published data show loh associated increase all-cause cvd-related mortality [7,149-152]. studies supported meta-analysis concluded hypogonadism risk factor cardiovascular morbidity mortality . importantly, men low testosterone compared eugonadal men angiographically proven coronary disease twice risk earlier death . longitudinal population studies reported men testosterone upper quartile normal range reduced number cv events compared men testosterone lower three quartiles . androgen deprivation therapy pca linked increased risk cvd sudden death . conversely, two long-term epidemiological studies reported reduced cv events men high normal serum testosterone levels . erectile dysfunction independently associated cvd may first clinical presentation men atherosclerosis. knowledge men hypogonadism and/or ed may underlying cvd prompt individual assessment cv risk profile. individual risk factors (e.g., lifestyle, diet, exercise, smoking, hypertension, diabetes dyslipidaemia) assessed treated men pre-existing cvd patients receiving androgen deprivation therapy. cardiovascular risk reduction managed primary care clinicians, patients appropriately counselled clinicians active prescribing testosterone therapy . appropriate, patients referred cardiologists risk stratification treatment comorbidity. rcts provided clear answer whether testosterone therapy affects cv outcomes. ttrial (n=790) conducted older men , times2 study (n=220) , along blast studies involving men metabolic syndrome (mets) type 2 diabetes mellitus (t2dm), well study involving pre-frail frail elderly men - lasted one year, t4dm study spanning two years - show increase major adverse cardiovascular events (mace) increase major adverse cardiovascular events (mace) . randomised controlled trials, three twelve months, men known heart disease treated testosterone found increase mace, reported improvement cardiac ischaemia, angina functional exercise capacity [159-161]. large cohort study (n=20,4857 men) found neither transdermal gel intramuscular testosterone associated increased risk composite cardiovascular outcome men without prevalent cvd (mean follow-up 4.3 years) . european medicines agency (ema) stated â€˜the co-ordination group mutual recognition decentralisation procedures-human (cmdh), regulatory body representing eu member states, agreed consensus consistent evidence increased risk heart problems testosterone men. however, product information updated line current available evidence safety, warnings lack testosterone confirmed signs symptoms laboratory tests treating men drugs . data recently released traverse study confirm findings ema . latter first double-blind, placebo-controlled, non-inferiority rct primary cv safety end point. results showed testosterone therapy noninferior placebo respect incidence mace. however, mild higher incidence atrial fibrillation, acute kidney injury, pulmonary embolism observed testosterone group . latter observations, however, need confirmed since previous available data support increased risk venous thromboembolism major arrhythmias testosterone therapy. similarly, long-term follow-up (median 5.1 years since last injection) t4dm study showed differences self-reported rates new diagnosis cvd . conclusion, current available data interventional studies suggest increased risk three years testosterone therapy [167-171]. currently published evidence reported testosterone therapy men diagnosed hypogonadism neutral beneficial actions mace patients normalised testosterone levels. findings could considered sufficiently reliable least three year course testosterone therapy, available study exclude long-term cv events . 3.5.5.1. cardiac failure testosterone therapy contraindicated men severe chronic cardiac failure fluid retention may lead exacerbation condition. studies shown men moderate chronic cardiac failure may benefit low doses testosterone, achieve mid-normal range testosterone levels . interesting observation untreated hypogonadism increased re-admission mortality rate men heart failure . decision made treat hypogonadism men chronic cardiac failure, essential patient followed carefully clinical assessment testosterone haematocrit measurements regular basis.